Aytu Biopharma (AYTU) Non Operating Interest Expenses (2010 - 2026)

Aytu Biopharma (AYTU) has reported Non Operating Interest Expenses for 15 consecutive years, with $436000.0 the latest figure, recorded in Q1 2026.

• On a quarterly basis, Non Operating Interest Expenses fell 51.56% year-over-year to $436000.0 in Q1 2026; TTM through Mar 2026 was $2.2 million, a 46.95% decrease from a year earlier, with the FY2025 full-year figure at $3.7 million, down 26.8% from the prior year.
• Non Operating Interest Expenses was $436000.0 for Q1 2026 at Aytu Biopharma, down from $560000.0 in the prior quarter.
• Over five years, Non Operating Interest Expenses peaked at $1.3 million in Q3 2023 and troughed at $436000.0 in Q1 2026.
• A 4-year average of $934000.0 and a median of $994000.0 in 2024 frame the typical range for Non Operating Interest Expenses.
• Across the five-year window, Non Operating Interest Expenses decreased 14.77% in 2024 and sank 51.56% in 2026, its largest moves.
• Over 4 years, Non Operating Interest Expenses stood at $1.3 million in 2023, then declined by 14.77% to $1.1 million in 2024, then slumped by 48.1% to $560000.0 in 2025, then retreated by 22.14% to $436000.0 in 2026.
• The last three Non Operating Interest Expenses figures came in at $436000.0 (Q1 2026), $560000.0 (Q4 2025), and $516000.0 (Q3 2025), per Business Quant data.